Articles by Nichole Tucker
BCMA–directed CAR Ts were a vital advancement to RRMM treatment. Now, oncologists wonder which agent works best.
Do IMID-containing quadruplet therapies represent both the present and future of myeloma treatment?
A retrospective study supported the safety of teclistamab and demonstrated a PFS benefit for patients with advanced myeloma.
Results from DALY II USA were presented during the oral abstract session on myeloma and lymphoma at the Tandem TCT Meetings.
Based on promising results from the phase II TELLOMAK study, the FDA grants a breakthrough therapy designation for lacutamab.
Findings from a subgroup analysis of ZUMA-7 support early referral to axi-cel therapy.
Real-world data suggest that treatment with either axi-cel or liso-cel provides potential to sustain disease-free survival.
Based on LINKER-MM1, FDA approval for linvoseltamab is under consideration.
The first study on the efficacy and safety of an IDH1 inhibitor and hypomethylating agent in advanced AML shows success.
Pirtobrutinib cut disease progression/death risk by 46% vs IdealaR/BR in heavily pretreated relapsed/refractory CLL/SLL.
Brentuximab Vedotin Combination Shows 37% Reduction in Risk of Death in Relapsed or Refractory DLBCL
Adding brentuximab vedotin to lenalidomide and rituximab significantly improved outcomes for patients with R/R DLBCL.
Extended follow-up was conducted for 652 patients with relapsed or refractory CLL or SLL in the ALPINE study.
Relmacabtagene autoleucel is an anti-CD19 chimeric antigen receptor T-cell product
A common treatment goal for polcythemia vera is to control HCT with therapy, phlebotomies, and cytoreductive therapies.
The 5-year follow-up analysis of ZUMA-5 showed continued efficacy and no new safety signals.
The phase 1b study of CAR22 is ongoing, and investigators are currently looking to enroll more patients.
SURPASS-ET compared second-line treatment with ropeginterferon alfa-2b with anagrelide in patients with ET.
Fludararabine lymphodepletion is more effective than bendamustine lymphodepletion, but more follow-up is needed to confirm.
Investigators looked into how intensified induction therapy impacts survival and MRD negativity in patients with AML.
Results from the phase I/II SAVE study in older and unfit patients with relapsed or refractory acute myeloid leukemia.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.